San Diego-centered Viking Therapeutics marked by itself as a serious competitor in the weight loss drug industry in February immediately after revealing promising details from a mid-phase demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when presented being a weekly injection and in March the compa